National Institute on Drug Abuse; Notice of Closed Meetings, 51966-51967 [2018-22309]
Download as PDF
<![CDATA[
51966
Federal Register / Vol. 83, No. 199 / Monday, October 15, 2018 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Post-Baccalaureate
Supplemental
Application.
Graduate Student Application ...........
Postdoctoral Fellowship Application
Reference Letter ...............................
Post-Baccalaureate (Including PostMaster’s) Individuals.
Graduate Students ...........................
Postdoctoral Candidates ..................
PIs, professors, supervisors .............
50
1
30/60
25
30
50
240
1
1
1
2
2
30/60
60
100
120
Totals .........................................
...........................................................
370
370
........................
305
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 5, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–22319 Filed 10–12–18; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2018–22311 Filed 10–12–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
khammond on DSK30JT082PROD with NOTICES
Average
time per
response
(in hours)
Type of
respondent
Dated: October 2, 2018.
Patricia M. Busche,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
Number of
respondents
Number of
responses
per
respondent
Form name
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Genomic Centers for
Infectious Diseases (U19 Clinical Trial Not
Allowed).
Date: November 8–9, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Eleazar Cohen, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G62A, National Institute of Health,
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20899823, (240) 669–5081,
ecohen@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
VerDate Sep<11>2014
21:34 Oct 12, 2018
Jkt 247001
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Peer Review Meeting.
Date: November 5, 2018.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Lee G. Klinkenberg, Ph.D.,
Scientific Review Program, DEA/NIAID/NIH/
DHHS, 5601 Fishers Lane, MSC–9823,
Bethesda, MD 20892–9834, 301–761–7749,
lee.klinkenberg@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Sexually Transmitted
Infections CRC: Vaccine Development (U19).
Date: November 8–9, 2018.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Total annual
burden hour
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Contact Person: Annie Walker-Abbey,
Ph.D., Scientific Review Officer, Scientific
Review Program, AID/NIH/DHHS, 5601
Fishers Lane, Room 3E70A, Rockville, MD
20852, 240–627–3390, aabbey@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 5, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–22312 Filed 10–12–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIH
Pathway to Independence Award (K99/R00).
Date: October 17, 2018.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\15OCN1.SGM
15OCN1
khammond on DSK30JT082PROD with NOTICES
Federal Register / Vol. 83, No. 199 / Monday, October 15, 2018 / Notices
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Blvd.,
Room 4245, Rockville, MD 20852, (301) 827–
5817, mcguireso@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; DeviceBased Treatments for Substance Use
Disorders (UG3/UH3) (Clinical Trial
Optional).
Date: October 22, 2018.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; CuttingEdge Basic Research Awards (CEBRA) (R21Clinical Trial Optional).
Date: October 24, 2018.
Time: 8:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Blvd.,
Room 4245, Rockville, MD 20852, (301) 827–
5817, mcguireso@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Development of Medications to Prevent and
Treat Opioid Use Disorders and Overdose
(UG3/UH3 (Clinical Trials Optional).
Date: November 15, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: Hilton Garden Inn Bethesda, 7301
Waverly Street, Bethesda, MD 20814.
Contact Person: Ivan K. Navarro, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4242, MSC 9550, Bethesda,
MD 20892, 301–827–5833, ivan.navarro@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
VerDate Sep<11>2014
21:34 Oct 12, 2018
Jkt 247001
Dated: October 5, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–22309 Filed 10–12–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. to achieve
expeditious commercialization of
results of federally-funded research and
development.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by emailing the indicated licensing
contact at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive any unpublished
information.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
High Density Lipoprotein (HDL)
Targeting Protease Inhibitor
Available for licensing and
commercial development is intellectual
property covering a class of lipoproteins
targeting protease inhibitors and
methods of their use for treating a
protease-mediated disease. Alpha-1antitrypsin (A1AT) deficiency occurs in
about 1 in 2500 individuals in the
United States and Europe. Persons with
this condition develop severe liver
disease and emphysema/chronic
obstructive pulmonary disease (COPD).
The current treatment for A1AT
deficiency includes intravenous
infusion of purified human A1AT
protein. This treatment strategy is
expensive and only moderately
effective. A recent study demonstrated
improvement in the treatment of A1AT
deficiency in a mouse model of
emphysema by pre-incubating A1AT
with high density lipoprotein (HDL)
particles prior to infusion. This resulted
in improvements in lung morphology
and inflammatory markers in the lung
PO 00000
Frm 00045
Fmt 4703
Sfmt 9990
51967
compared to A1AT treatment alone. The
mechanism for this improvement in
function of A1AT when bound to HDL
is believed to be increased trafficking of
A1AT to the lung. The lipoprotein
targeting protease inhibitory peptide of
the present invention represents
provides advances upon these existing
methods. First, it replaces the need for
full length A1AT protein with a known
small peptide inhibitor of elastase (the
natural target protease of A1AT; a small
tetra-peptide with the sequence Ala-AlaPro-Val-chloromethylketone). Second,
the peptide can be conjugated by amine
reactive chemistry to a lipoprotein
targeting motif. The inventors have data
linking the peptide to a Vitamin E with
a polyethylene glycol spacer arm to
distance the functional AAPV peptide
from the targeting moiety and to provide
improved solubility. Third, the
approach promises improved efficacy
over the current standard of care (A1AT
infusion) because the overall molecule
is small molecule, 2.5 kDa versus 52
kDa for the the full length A1AT
protein. An HDL particle can generally
accommodate only one molecule of
A1AT, whereas many copies of our
VitE–PEG–AAPV peptide can reside on
an HDL particle providing a significant
increase in potency.
Potential Commercial Applications
• Alpha-1-antitrypsin deficiency
• severe liver disease
• emphysema/chronic obstructive
pulmonary disease
Development Stage
• Early stage
Inventors: Alan Remaley and Scott
Maxwell Gordon (both of NHLBI)
Relevant Publications: Gordon, et al.
Molecular & Cellular Proteomics 14:
10.1074/mcp.M115.054031, 3247–3257,
2015.
Intellectual Property: HHS Reference
No. E–155–2016; U.S Patent Application
15/297,054 filed October 18, 2016.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Dated: September 24, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2018–22316 Filed 10–12–18; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\15OCN1.SGM
15OCN1
]]>Agencies
[Federal Register Volume 83, Number 199 (Monday, October 15, 2018)]
[Notices]
[Pages 51966-51967]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-22309]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIH Pathway to Independence Award (K99/R00).
Date: October 17, 2018.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
[[Page 51967]]
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Contact Person: Susan O. McGuire, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive
Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Device-Based Treatments for Substance Use Disorders
(UG3/UH3) (Clinical Trial Optional).
Date: October 22, 2018.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892,
301-827-5840, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Cutting-Edge Basic Research Awards (CEBRA) (R21-
Clinical Trial Optional).
Date: October 24, 2018.
Time: 8:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Contact Person: Susan O. McGuire, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive
Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Development of Medications to Prevent and Treat
Opioid Use Disorders and Overdose (UG3/UH3 (Clinical Trials
Optional).
Date: November 15, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: Hilton Garden Inn Bethesda, 7301 Waverly Street,
Bethesda, MD 20814.
Contact Person: Ivan K. Navarro, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892,
301-827-5833, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: October 5, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-22309 Filed 10-12-18; 8:45 am]
BILLING CODE 4140-01-P
